Abstract
The effect(s) of purified transforming growth factor-beta (TGF-beta) and platelet-derived growth factor (PDGF) on the induction and function of lymphokine-activated killer (LAK) cells and cytotoxic T lymphocytes (CTL) was examined. The addition of TGF-beta, but not PDGF, to cultures containing fresh C57BL/6 mouse splenocytes or human peripheral blood lymphocytes plus recombinant interleukin-2 markedly inhibited the development of mouse and human LAK cell activity (measured after 3 days for cytotoxicity against cultured or fresh tumor targets in 4-h 51Cr release assays). The addition of TGF-beta, but not PDGF, to a one-way, C57BL/6 anti-DBA/2, mixed lymphocyte reaction effectively blocked the generation of allospecific CTL as well. However, TGF-beta did not inhibit the effector function of LAK cells or of allospecific CTL when added directly to the short-term cytolytic assay. A second form of homodimeric TGF-beta, type 2, was also found to be suppressive on the development of murine LAK cells and allospecific CTL. Collectively, these data demonstrate that the peptide TGF-beta is a potent inhibitor of LAK cell and CTL generation in vitro.
Keywords: Peripheral Blood Lymphocyte, Human Peripheral Blood, Release Assay, Mixed Lymphocyte Reaction, Human Peripheral Blood Lymphocyte
References
- 1.Anzano MA, Roberts AB, DeLarco JE, Wakefield LM, Assoian RK, Roche NS, Smith JM, Lazarus JE, Sporn MB. Increased secretion of type beta transforming growth factor accompanies viral transformation of cells. Mol Cell Biol. 1985;5:242. doi: 10.1128/mcb.5.1.242. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Assoian RK, Komoriya A, Meyers CA, Sporn MB. Transforming growth factor-beta in human platelets: identification of a major storage site, purification, and characterization. J Biol Chem. 1983;258:7155. [PubMed] [Google Scholar]
- 3.Brooks WM, Netsky MG, Normansell DE, Horwitz DA. Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med. 1972;136:1631. doi: 10.1084/jem.136.6.1631. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Cheever MA, Britzmann D, Thompson J, Klarnet JP, Greenberg PD. Antigen-driven long-term cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory cells. J Exp Med. 1986;163:1100. doi: 10.1084/jem.163.5.1100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Cheifetz S, Weatherbee JA, Tsang ML-S, Anderson JK, Mole JE, Lucas R, Massague J. The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. Cell. 1987;48:409. doi: 10.1016/0092-8674(87)90192-9. [DOI] [PubMed] [Google Scholar]
- 6.Derynck R, Jarret JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature. 1985;316:701. doi: 10.1038/316701a0. [DOI] [PubMed] [Google Scholar]
- 7.Donohue JH, Rosenberg SA. The fate of interleukin-2 after in vivo administration. J Immunol. 1983;130:2203. [PubMed] [Google Scholar]
- 8.Donohue JH, Rosenstein M, Chang AE, Lotze MT, Robb RJ, Rosenberg SA. The systemic administration of purified interleukin-2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. J Immunol. 1984;132:2123. [PubMed] [Google Scholar]
- 9.Farram E, Nelson M, Nelson DS, Moon DK. Inhibition of cytokine production by a tumor cell product. Immunology. 1982;46:603. [PMC free article] [PubMed] [Google Scholar]
- 10.Greenberg PD. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: Cytolytic T cells can mediate eradication of disseminated leukemia. J Immunol. 1986;136:1917. [PubMed] [Google Scholar]
- 11.Hellström KE, Hellström I. Enhancement of tumor outgrowth by tumor-associated blocking factors. Int J Cancer. 1979;23:336. doi: 10.1002/ijc.2910230315. [DOI] [PubMed] [Google Scholar]
- 12.Hersey P, Bindon C, Czernieski M, Spurline A, Wass J, McCarthy WH. Inhibition of interleukin 2 production by factors released from tumor cells. J Immunol. 1983;131:2837. [PubMed] [Google Scholar]
- 13.Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS. Production of transforming growth factor-beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med. 1986;163:1037. doi: 10.1084/jem.163.5.1037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Kehrl JR, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS. Transforming growth factor-beta is an important immunomodulatory protein for human B lymphocytes. J Immunol. 1986;137:3855. [PubMed] [Google Scholar]
- 15.Kikuchi K, Neuwelt EA. J Neurosurg. 1983;59:790. doi: 10.3171/jns.1983.59.5.0790. [DOI] [PubMed] [Google Scholar]
- 16.Kim B, Rosenstein M, Weiland D, Eberlein TJ, Rosenberg SA. Mediation of graft rejection in vivo by cloned Lyt-1+2− proliferative, noncytotoxic long-term cell lines. Transplantion. 1983;36:526. doi: 10.1097/00007890-198311000-00011. [DOI] [PubMed] [Google Scholar]
- 17.Lafreniere R, Rosenberg SA. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2. Cancer Res. 1985;45:3735. [PubMed] [Google Scholar]
- 18.Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA. High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: Responses, treatment related morbidity, and histologic findings. J Am Med Assoc. 1986;256:3117. [PubMed] [Google Scholar]
- 19.Miescher S, Whiteside TL, Carrel S, von Fliedner V. Functional properties of tumor infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol. 1986;136:1899. [PubMed] [Google Scholar]
- 20.Mulé JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science. 1984;225:1487. doi: 10.1126/science.6332379. [DOI] [PubMed] [Google Scholar]
- 21.Mulé JJ, Yang J, Shu S, Rosenberg SA. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: Direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. J Immunol. 1986;136:3899. [PubMed] [Google Scholar]
- 22.Mulé JJ, Yang JC, Lafreniere R, Shu S, Rosenberg SA. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. J Immunol. 1987;139:285. [PubMed] [Google Scholar]
- 23.Parker GA, Rosenberg SA. Serologic identification of multiple tumor-associated antigens on murine sarcomas. J Natl Cancer Inst. 1977;58:1303. doi: 10.1093/jnci/58.5.1303. [DOI] [PubMed] [Google Scholar]
- 24.Putnam JB, Roth JA. Identification and characterization of a tumor-derived immunosuppressive glycoprotein from murine melanoma K-1735. Cancer Immunol Immunother. 1985;19:90. doi: 10.1007/BF00199715. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Roberts AB, Sporn MB (1987) Transforming growth factor-beta. Adv Cancer Res (in press) [PubMed]
- 26.Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB. New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci USA. 1981;78:5339. doi: 10.1073/pnas.78.9.5339. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Roberts AB, Frolik CA, Anzano MA, Sporn MB. Transforming growth factors from neoplastic and nonneoplastic tissues. Fed Proc. 1983;42:2621. [PubMed] [Google Scholar]
- 28.Rong GH, Grimm EA, Sindelar WF. An enzymatic method for the consistent production of monodispersed viable cell suspensions for human solid tumors. J Surg Oncol. 1985;20:131. doi: 10.1002/jso.2930280213. [DOI] [PubMed] [Google Scholar]
- 29.Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, Lane HC, Fauci AS. Effects of transforming growth factor-beta on the functions of natural killer cells: Depressed cytolytic activity and blunting of interferon responsiveness. J Immunol. 1986;136:3916. [PubMed] [Google Scholar]
- 30.Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark DF. Biological activity of recombinant human interleukin-2 produced in Escherichia coli . Science. 1984;223:1412. doi: 10.1126/science.6367046. [DOI] [PubMed] [Google Scholar]
- 31.Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Reichert CM. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;303:1485. doi: 10.1056/NEJM198512053132327. [DOI] [PubMed] [Google Scholar]
- 32.Rosenberg SA, Mulé JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med. 1985;161:1169. doi: 10.1084/jem.161.5.1169. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;223:1318. doi: 10.1126/science.3489291. [DOI] [PubMed] [Google Scholar]
- 34.Rosenstein M, Eberlein T, Kemeny MM, Sugarbaker PH, Rosenberg SA. In vitro growth of murine T cells. VI. Accelerated skin graft rejection caused by adoptively transferred cells expanded in T cell growth factor. J Immunol. 1982;127:566. [PubMed] [Google Scholar]
- 35.Rosenstein M, Yron I, Kaufmann Y, Rosenberg SA. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin-2. Cancer Res. 1984;44:1946. [PubMed] [Google Scholar]
- 36.Seyedin SM, Thomas TC, Thompson AY, Rosen DM, Piez KA. Purification and characterization of two cartilage-inducing factors from bovine demineralized bone. Proc Natl Acad Sci USA. 1985;82:2267. doi: 10.1073/pnas.82.8.2267. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Shu S, Chou T, Rosenberg SA. In vitro sensitization and expansion with viable tumor cells and interleukin-2 in the generation of specific therapeutic effector cells. J Immunol. 1986;136:3891. [PubMed] [Google Scholar]
- 38.Sjogren HO, Hellström I. Induction of polyoma specific transplantation antigenicity in Maloney leukemia cells. Exp Cell Res. 1965;40:208. doi: 10.1016/0014-4827(65)90319-8. [DOI] [PubMed] [Google Scholar]
- 39.Spiess PJ, Yang JC, Rosenberg SA. The in vivo anti-tumor activity of tumor infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst. 1987;79:1067. [PubMed] [Google Scholar]
- 40.Sporn MB, Roberts AB, Wakefield LM, Assoian RK. Transforming growth factor-beta: biological function and chemical structure. Science. 1986;233:532. doi: 10.1126/science.3487831. [DOI] [PubMed] [Google Scholar]
- 41.Strausser JL, Rosenberg SA. In vitro growth of cytotoxic human lymphocytes. I. Growth of cells sensitized in vitro to alloantigens. J Immunol. 1978;121:1951. [PubMed] [Google Scholar]
- 42.Wrann M, Bodmer S, de Martin R, Siepl C, Hofer-Warbinek R, Frei K, Hofer E, Fontana A (1987) T cell suppressor factor from human glioblastoma cells is a 12.5 Kd protein closely related to transforming growth factor-beta. EMBO J (in press) [DOI] [PMC free article] [PubMed]